Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
1500003O 03Rik | |
NM_019769 |
RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] |
KLA | .92 |
.89 |
.89 |
.86 |
.85 |
.92 |
1.08 |
| ATP | 1.01 |
1.16 |
1.16 |
1.53 |
1.70 |
3.33 |
2.09 |
| KLA/ATP | .89 |
.97 |
.93 |
1.17 |
1.19 |
2.86 |
2.57 |
|
2010110P 09Rik | |
NM_027363 |
RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] |
KLA | .99 |
.98 |
1.02 |
.99 |
.94 |
1.01 |
1.01 |
| ATP | 1.04 |
1.05 |
.97 |
1.05 |
.95 |
.98 |
.95 |
| KLA/ATP | .93 |
1.00 |
1.02 |
.97 |
1.01 |
.96 |
.97 |
|
AK036998
| |
AK036998 |
adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] |
KLA | 1.43 |
1.09 |
.89 |
.79 |
.96 |
.97 |
.71 |
| ATP | 1.04 |
1.04 |
.71 |
.64 |
.90 |
.82 |
.82 |
| KLA/ATP | 1.34 |
1.23 |
1.01 |
.89 |
1.10 |
.82 |
.75 |
|
Aifm1 | |
NM_012019 |
apoptosis-inducing factor, mitochondrion-associated 1 (Aifm1), nuclear gene encoding mitochondrial protein, mRNA [NM_012019] |
KLA | .85 |
.82 |
.80 |
.72 |
.63 |
.66 |
.74 |
| ATP | 1.04 |
1.00 |
1.18 |
1.12 |
1.55 |
2.04 |
.89 |
| KLA/ATP | .82 |
.86 |
.94 |
.81 |
.86 |
1.09 |
.63 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Apaf1 | |
NM_001042558 |
apoptotic peptidase activating factor 1 (Apaf1), transcript variant 1, mRNA [NM_001042558] |
KLA | 2.92 |
2.81 |
3.22 |
2.74 |
2.42 |
1.74 |
1.40 |
| ATP | 1.05 |
.99 |
.87 |
.81 |
1.61 |
2.03 |
1.46 |
| KLA/ATP | 2.90 |
2.78 |
2.01 |
1.69 |
1.56 |
2.77 |
2.73 |
|
Atm | |
NM_007499 |
ataxia telangiectasia mutated homolog (human) (Atm), mRNA [NM_007499] |
KLA | 1.86 |
1.97 |
2.17 |
1.67 |
1.20 |
.86 |
.79 |
| ATP | 1.09 |
1.17 |
1.01 |
.97 |
.61 |
.63 |
.69 |
| KLA/ATP | 2.11 |
2.24 |
1.55 |
1.46 |
.85 |
.75 |
.59 |
|
Bad | |
AK029400 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] |
KLA | 1.15 |
1.22 |
1.26 |
1.31 |
1.40 |
1.67 |
1.59 |
| ATP | .95 |
1.06 |
1.12 |
1.06 |
.78 |
.89 |
1.27 |
| KLA/ATP | 1.25 |
1.39 |
1.33 |
1.29 |
1.11 |
.91 |
1.38 |
|
Bax | |
NM_007527 |
Bcl2-associated X protein (Bax), mRNA [NM_007527] |
KLA | 1.08 |
1.14 |
1.10 |
1.14 |
1.17 |
1.06 |
.92 |
| ATP | 1.06 |
1.05 |
1.02 |
1.25 |
1.26 |
.90 |
.86 |
| KLA/ATP | 1.11 |
1.19 |
1.30 |
1.34 |
1.34 |
.87 |
.71 |
|
Bcl2 | |
NM_009741 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] |
KLA | .30 |
.26 |
.25 |
.25 |
.34 |
.38 |
.26 |
| ATP | .97 |
.89 |
1.50 |
1.04 |
.99 |
.29 |
.52 |
| KLA/ATP | .28 |
.26 |
.40 |
.33 |
.62 |
.29 |
.12 |
|
Bcl2 | |
NM_177410 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] |
KLA | .33 |
.33 |
.37 |
.42 |
.49 |
.46 |
.39 |
| ATP | 1.07 |
1.12 |
1.22 |
1.56 |
1.00 |
.38 |
.76 |
| KLA/ATP | .35 |
.34 |
.54 |
.89 |
.76 |
.36 |
.23 |
|
Bcl2l1 | |
NM_009743 |
Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] |
KLA | .99 |
1.02 |
1.10 |
1.16 |
1.27 |
.97 |
1.05 |
| ATP | 1.18 |
1.42 |
.81 |
1.26 |
1.51 |
.71 |
1.67 |
| KLA/ATP | 1.21 |
1.30 |
.66 |
1.15 |
1.31 |
1.17 |
1.59 |
|
Bid | |
NM_007544 |
BH3 interacting domain death agonist (Bid), mRNA [NM_007544] |
KLA | 1.03 |
1.08 |
1.09 |
1.14 |
1.01 |
.99 |
.68 |
| ATP | 1.06 |
1.11 |
.97 |
.89 |
1.04 |
1.17 |
1.08 |
| KLA/ATP | .88 |
1.09 |
.92 |
1.06 |
1.16 |
1.28 |
1.56 |
|
Birc2 | |
NM_007465 |
baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] |
KLA | 4.63 |
4.59 |
3.77 |
2.79 |
2.32 |
2.07 |
1.84 |
| ATP | .95 |
.88 |
.84 |
.92 |
.76 |
1.34 |
1.28 |
| KLA/ATP | 4.70 |
4.93 |
4.13 |
2.60 |
1.34 |
1.60 |
2.31 |
|
Birc3 | |
BC011338 |
baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] |
KLA | 5.48 |
5.46 |
4.94 |
4.16 |
4.91 |
3.36 |
3.74 |
| ATP | 1.05 |
1.08 |
4.21 |
4.28 |
2.59 |
2.55 |
1.57 |
| KLA/ATP | 6.78 |
8.91 |
11.01 |
4.87 |
2.28 |
2.12 |
3.66 |
|
Birc3 | |
NM_007464 |
baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] |
KLA | 17.83 |
15.88 |
13.48 |
11.14 |
11.79 |
6.90 |
6.10 |
| ATP | 1.14 |
1.16 |
1.70 |
4.07 |
5.00 |
6.33 |
2.41 |
| KLA/ATP | 14.77 |
16.44 |
19.09 |
13.91 |
8.27 |
6.22 |
7.73 |
|
Birc7 | |
AK053463 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130019N06 product:weakly similar to BA261N11.1.3 (BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7 (LIVIN), ISOFORM 3) (FRAGMENT) [Homo sapiens], full insert sequence [AK05 |
KLA | 1.02 |
1.02 |
.93 |
1.01 |
.91 |
1.27 |
1.07 |
| ATP | 1.02 |
1.03 |
.99 |
.93 |
.96 |
.98 |
1.01 |
| KLA/ATP | 1.00 |
1.04 |
.97 |
.94 |
.91 |
.93 |
.92 |
|
Capn1 | |
NM_007600 |
calpain 1 (Capn1), transcript variant 1, mRNA [NM_007600] |
KLA | 1.28 |
1.27 |
1.46 |
1.23 |
1.37 |
1.27 |
.99 |
| ATP | 1.07 |
1.24 |
.99 |
1.33 |
.98 |
.89 |
1.21 |
| KLA/ATP | 1.46 |
1.49 |
1.09 |
1.57 |
1.03 |
1.18 |
1.28 |
|
Capn2 | |
NM_009794 |
calpain 2 (Capn2), mRNA [NM_009794] |
KLA | .63 |
.65 |
.70 |
.57 |
.60 |
.61 |
.58 |
| ATP | 1.03 |
1.21 |
.78 |
.98 |
.82 |
.59 |
1.19 |
| KLA/ATP | .80 |
.71 |
.37 |
.54 |
.45 |
.46 |
1.05 |
|
Casp12 | |
NM_009808 |
caspase 12 (Casp12), mRNA [NM_009808] |
KLA | 6.56 |
6.38 |
7.54 |
6.85 |
5.36 |
2.61 |
1.46 |
| ATP | .99 |
.98 |
1.17 |
1.56 |
1.32 |
1.40 |
1.13 |
| KLA/ATP | 6.27 |
6.52 |
5.79 |
5.68 |
3.74 |
2.21 |
1.78 |
|
Casp3 | |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
Casp3 | |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
Casp6 | |
NM_009811 |
caspase 6 (Casp6), mRNA [NM_009811] |
KLA | .82 |
.78 |
.80 |
.80 |
.67 |
.60 |
.61 |
| ATP | .95 |
.92 |
1.18 |
1.08 |
.84 |
1.60 |
.72 |
| KLA/ATP | .76 |
.73 |
.90 |
.80 |
.72 |
1.30 |
.80 |
|
Casp7 | |
NM_007611 |
caspase 7 (Casp7), mRNA [NM_007611] |
KLA | 3.50 |
3.60 |
4.52 |
5.05 |
5.20 |
2.96 |
1.27 |
| ATP | 1.03 |
1.14 |
1.20 |
1.27 |
.82 |
.77 |
.84 |
| KLA/ATP | 3.32 |
3.86 |
3.98 |
5.27 |
3.49 |
2.55 |
2.30 |
|
Casp8 | |
NM_009812 |
caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] |
KLA | 2.41 |
2.53 |
3.20 |
3.26 |
2.75 |
2.78 |
1.57 |
| ATP | .91 |
.96 |
.66 |
.67 |
.54 |
1.53 |
1.52 |
| KLA/ATP | 2.47 |
2.52 |
2.08 |
2.41 |
1.41 |
2.50 |
2.77 |
|
Casp9 | |
NM_015733 |
caspase 9 (Casp9), mRNA [NM_015733] |
KLA | .31 |
.31 |
.40 |
.66 |
.89 |
1.19 |
.91 |
| ATP | .88 |
.77 |
.91 |
.59 |
.43 |
.75 |
.93 |
| KLA/ATP | .26 |
.26 |
.30 |
.28 |
.80 |
1.06 |
.97 |
|
Cflar | |
NM_009805 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 2, mRNA [NM_009805] |
KLA | 18.63 |
20.03 |
20.30 |
17.44 |
17.99 |
11.88 |
7.25 |
| ATP | .95 |
1.03 |
1.20 |
2.78 |
4.04 |
3.45 |
3.30 |
| KLA/ATP | 19.31 |
19.09 |
11.65 |
13.57 |
7.62 |
6.20 |
11.21 |
|
Cflar | |
NM_207653 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 1, mRNA [NM_207653] |
KLA | 12.32 |
12.86 |
11.83 |
11.79 |
12.14 |
8.52 |
5.42 |
| ATP | .92 |
.92 |
1.63 |
4.97 |
7.95 |
5.18 |
2.39 |
| KLA/ATP | 12.27 |
13.57 |
13.15 |
12.79 |
10.27 |
7.71 |
8.32 |
|
Cflar | |
Y14041 |
mRNA for CASH alpha protein. [Y14041] |
KLA | 14.31 |
13.82 |
13.05 |
13.06 |
14.36 |
9.02 |
5.92 |
| ATP | 1.18 |
1.15 |
1.66 |
6.44 |
8.99 |
5.20 |
2.73 |
| KLA/ATP | 15.53 |
17.07 |
14.00 |
17.10 |
10.76 |
8.02 |
9.97 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Csf2rb | |
NM_007780 |
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (Csf2rb), mRNA [NM_007780] |
KLA | 1.35 |
1.52 |
1.85 |
1.87 |
2.61 |
2.52 |
2.54 |
| ATP | 1.09 |
1.15 |
1.08 |
1.83 |
6.59 |
6.78 |
7.07 |
| KLA/ATP | 1.55 |
1.66 |
1.38 |
2.67 |
6.21 |
6.94 |
6.57 |
|
Csf2rb2 | |
NM_007781 |
colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage) (Csf2rb2), mRNA [NM_007781] |
KLA | .78 |
.77 |
.81 |
1.04 |
1.45 |
1.45 |
1.91 |
| ATP | 1.12 |
1.03 |
.89 |
1.11 |
6.65 |
7.45 |
8.58 |
| KLA/ATP | .87 |
.87 |
.84 |
1.09 |
4.89 |
7.15 |
8.83 |
|
Cycs | |
NM_007808 |
cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] |
KLA | 2.20 |
2.21 |
2.35 |
2.69 |
2.62 |
3.22 |
2.14 |
| ATP | .87 |
.89 |
1.31 |
1.05 |
1.06 |
1.20 |
1.26 |
| KLA/ATP | 1.88 |
2.04 |
2.86 |
2.26 |
2.57 |
2.45 |
2.03 |
|
Cyct | |
NM_009989 |
cytochrome c, testis (Cyct), mRNA [NM_009989] |
KLA | .93 |
1.01 |
1.00 |
.99 |
1.02 |
1.03 |
.96 |
| ATP | 1.01 |
.91 |
1.01 |
.99 |
.98 |
.95 |
.95 |
| KLA/ATP | 1.10 |
.96 |
.89 |
.89 |
1.10 |
1.05 |
.97 |
|
Dffa | |
NM_001025296 |
DNA fragmentation factor, alpha subunit (Dffa), transcript variant 1, mRNA [NM_001025296] |
KLA | .96 |
.94 |
.93 |
.86 |
1.01 |
.91 |
.92 |
| ATP | 1.11 |
1.16 |
1.09 |
1.09 |
.73 |
.64 |
.83 |
| KLA/ATP | 1.02 |
1.02 |
.97 |
1.04 |
.67 |
.61 |
.69 |
|
Dffa | |
NM_010044 |
DNA fragmentation factor, alpha subunit (Dffa), transcript variant 2, mRNA [NM_010044] |
KLA | .85 |
.92 |
1.01 |
.94 |
.98 |
.88 |
.91 |
| ATP | 1.07 |
1.08 |
1.11 |
1.08 |
.80 |
.65 |
1.04 |
| KLA/ATP | .99 |
1.00 |
1.03 |
1.00 |
.74 |
.69 |
.71 |
|
Dffb | |
NM_007859 |
DNA fragmentation factor, beta subunit (Dffb), mRNA [NM_007859] |
KLA | .94 |
.81 |
.86 |
.86 |
.92 |
.90 |
.82 |
| ATP | 1.01 |
.90 |
.64 |
.60 |
.87 |
1.11 |
.93 |
| KLA/ATP | .84 |
.75 |
.71 |
.72 |
.90 |
.98 |
.80 |
|
Endog | |
NM_007931 |
endonuclease G (Endog), nuclear gene encoding mitochondrial protein, mRNA [NM_007931] |
KLA | .78 |
.76 |
.68 |
.66 |
.68 |
.77 |
1.12 |
| ATP | .99 |
1.08 |
.99 |
1.06 |
.71 |
.98 |
1.11 |
| KLA/ATP | .73 |
.74 |
.62 |
.69 |
.58 |
.93 |
.67 |
|
Fadd | |
NM_010175 |
Fas (TNFRSF6)-associated via death domain (Fadd), mRNA [NM_010175] |
KLA | .54 |
.54 |
.59 |
.64 |
.80 |
.97 |
1.16 |
| ATP | 1.05 |
1.09 |
1.03 |
1.65 |
1.18 |
.78 |
1.61 |
| KLA/ATP | .56 |
.56 |
.53 |
.78 |
.78 |
.82 |
1.34 |
|
Fas | |
AK086933 |
0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] |
KLA | 6.31 |
6.56 |
6.33 |
6.70 |
4.93 |
3.74 |
2.48 |
| ATP | .95 |
1.04 |
1.33 |
1.55 |
1.85 |
6.00 |
2.77 |
| KLA/ATP | 5.67 |
7.16 |
7.71 |
7.73 |
6.02 |
5.79 |
7.85 |
|
Fas | |
NM_007987 |
Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] |
KLA | 17.08 |
17.45 |
19.08 |
17.38 |
13.33 |
6.78 |
4.46 |
| ATP | .98 |
.96 |
1.64 |
3.05 |
5.58 |
12.91 |
1.89 |
| KLA/ATP | 16.57 |
17.25 |
26.06 |
23.57 |
22.03 |
16.74 |
13.29 |
|
Fasl | |
NM_010177 |
Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] |
KLA | 1.03 |
1.01 |
1.03 |
1.02 |
1.01 |
1.01 |
1.00 |
| ATP | 1.00 |
.99 |
1.04 |
1.21 |
1.18 |
1.20 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
1.07 |
1.16 |
1.18 |
1.23 |
1.00 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il1a | |
NM_010554 |
interleukin 1 alpha (Il1a), mRNA [NM_010554] |
KLA | 32.45 |
35.22 |
31.30 |
20.95 |
28.57 |
18.36 |
19.02 |
| ATP | 1.04 |
1.02 |
2.21 |
5.46 |
11.06 |
32.07 |
3.40 |
| KLA/ATP | 32.02 |
41.20 |
35.12 |
46.91 |
28.76 |
42.72 |
57.80 |
|
Il1b | |
NM_008361 |
interleukin 1 beta (Il1b), mRNA [NM_008361] |
KLA | 149.78 |
133.59 |
100.91 |
116.58 |
86.48 |
89.37 |
64.72 |
| ATP | 3.49 |
13.96 |
61.44 |
70.91 |
82.12 |
162.79 |
28.18 |
| KLA/ATP | 130.32 |
139.00 |
219.12 |
148.17 |
165.44 |
172.57 |
146.98 |
|
Il1r1 | |
NM_008362 |
interleukin 1 receptor, type I (Il1r1), transcript variant 1, mRNA [NM_008362] |
KLA | 1.20 |
1.08 |
1.22 |
1.52 |
2.19 |
2.32 |
1.61 |
| ATP | 1.10 |
.96 |
1.18 |
1.56 |
8.14 |
9.56 |
7.54 |
| KLA/ATP | 1.22 |
1.13 |
1.37 |
1.85 |
4.54 |
6.85 |
8.96 |
|
Il1rap | |
AK032620 |
adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430709H04 product:unclassifiable, full insert sequence [AK032620] |
KLA | 1.05 |
.98 |
1.07 |
.95 |
.98 |
.95 |
.92 |
| ATP | .95 |
.98 |
1.05 |
1.01 |
.94 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.07 |
1.07 |
1.10 |
.99 |
1.03 |
1.01 |
|
Il1rap | |
AK045686 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230304B05 product:interleukin 1 receptor accessory protein, full insert sequence [AK045686] |
KLA | 2.25 |
2.43 |
2.55 |
2.32 |
2.32 |
1.35 |
.81 |
| ATP | 1.13 |
1.31 |
1.25 |
1.28 |
1.04 |
1.28 |
.75 |
| KLA/ATP | 2.49 |
2.48 |
1.87 |
2.62 |
1.83 |
1.50 |
.77 |
|
Il1rap | |
NM_008364 |
interleukin 1 receptor accessory protein (Il1rap), transcript variant 1, mRNA [NM_008364] |
KLA | 1.11 |
1.16 |
1.17 |
1.15 |
1.11 |
.97 |
.97 |
| ATP | 1.02 |
1.12 |
1.07 |
1.03 |
1.01 |
.98 |
.84 |
| KLA/ATP | 1.20 |
1.19 |
1.07 |
1.10 |
.98 |
1.06 |
.89 |
|
Il1rap | |
NM_134103 |
interleukin 1 receptor accessory protein (Il1rap), transcript variant 2, mRNA [NM_134103] |
KLA | 1.42 |
1.42 |
1.46 |
1.39 |
1.40 |
1.14 |
.90 |
| ATP | 1.10 |
1.16 |
1.22 |
1.04 |
.98 |
.81 |
.79 |
| KLA/ATP | 1.45 |
1.53 |
1.33 |
1.33 |
1.08 |
.98 |
.75 |
|
Il3 | |
NM_010556 |
interleukin 3 (Il3), mRNA [NM_010556] |
KLA | 1.05 |
.94 |
1.01 |
.99 |
1.03 |
1.07 |
.95 |
| ATP | .95 |
1.03 |
1.03 |
.98 |
.98 |
.97 |
.96 |
| KLA/ATP | 1.02 |
1.03 |
1.02 |
.94 |
.97 |
1.02 |
1.04 |
|
Il3ra | |
NM_008369 |
interleukin 3 receptor, alpha chain (Il3ra), mRNA [NM_008369] |
KLA | 1.23 |
1.35 |
1.52 |
1.31 |
1.38 |
1.42 |
1.35 |
| ATP | 1.04 |
1.20 |
1.11 |
1.42 |
1.18 |
.94 |
.77 |
| KLA/ATP | 1.33 |
1.45 |
1.45 |
1.69 |
1.25 |
1.22 |
1.32 |
|
Irak1 | |
NM_008363 |
interleukin-1 receptor-associated kinase 1 (Irak1), mRNA [NM_008363] |
KLA | .67 |
.67 |
.64 |
.56 |
.58 |
.58 |
.84 |
| ATP | 1.02 |
1.10 |
.94 |
1.14 |
.81 |
.54 |
.87 |
| KLA/ATP | .72 |
.72 |
.57 |
.67 |
.51 |
.43 |
.62 |
|
Irak2 | |
NM_172161 |
interleukin-1 receptor-associated kinase 2 (Irak2), transcript variant 1, mRNA [NM_172161] |
KLA | 8.24 |
8.89 |
7.70 |
6.43 |
6.61 |
4.53 |
3.48 |
| ATP | 1.06 |
1.22 |
1.26 |
2.10 |
4.99 |
4.55 |
2.69 |
| KLA/ATP | 8.32 |
9.13 |
7.57 |
7.95 |
5.01 |
6.84 |
8.36 |
|
Irak3 | |
NM_028679 |
interleukin-1 receptor-associated kinase 3 (Irak3), mRNA [NM_028679] |
KLA | 2.04 |
2.22 |
2.80 |
3.81 |
6.02 |
4.81 |
6.76 |
| ATP | 1.13 |
1.14 |
1.02 |
1.26 |
.97 |
2.51 |
1.31 |
| KLA/ATP | 2.24 |
2.35 |
2.06 |
2.58 |
1.43 |
1.55 |
4.63 |
|
Irak4 | |
NM_029926 |
interleukin-1 receptor-associated kinase 4 (Irak4), mRNA [NM_029926] |
KLA | .82 |
.86 |
.78 |
.82 |
.95 |
1.21 |
1.22 |
| ATP | 1.02 |
1.18 |
.95 |
1.10 |
.79 |
.85 |
.82 |
| KLA/ATP | .86 |
.89 |
.77 |
.90 |
.78 |
.96 |
.88 |
|
Map3k14 | |
NM_016896 |
mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] |
KLA | .32 |
.30 |
.40 |
.52 |
1.08 |
1.14 |
.94 |
| ATP | 1.18 |
1.24 |
1.13 |
.85 |
.82 |
.84 |
.99 |
| KLA/ATP | .33 |
.30 |
.34 |
.50 |
1.02 |
.84 |
1.43 |
|
Mm.15898 1 | |
142388182 |
Unknown |
KLA | .25 |
.22 |
.31 |
.50 |
.85 |
1.11 |
.83 |
| ATP | 1.02 |
.94 |
1.31 |
.76 |
.73 |
.96 |
.92 |
| KLA/ATP | .24 |
.22 |
.34 |
.38 |
1.16 |
.96 |
1.23 |
|
Mm.18787 9 | |
149250519 |
Unknown |
KLA | .98 |
.98 |
1.02 |
1.05 |
1.01 |
1.10 |
1.02 |
| ATP | 1.03 |
1.00 |
.98 |
1.02 |
1.02 |
1.04 |
.99 |
| KLA/ATP | .99 |
1.07 |
1.04 |
1.02 |
.94 |
.97 |
.93 |
|
Mm.21312 8 | |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.25381 9 | |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.30616 3 | |
31543508 |
Unknown |
KLA | .75 |
.79 |
.72 |
.74 |
.73 |
.95 |
1.15 |
| ATP | .93 |
.93 |
1.13 |
1.15 |
1.30 |
1.17 |
1.64 |
| KLA/ATP | .78 |
.83 |
.82 |
.86 |
1.02 |
1.17 |
1.18 |
|
Mm.33138 9 | |
158508469 |
Unknown |
KLA | .80 |
.79 |
.81 |
.82 |
.72 |
.64 |
.50 |
| ATP | .95 |
.85 |
.56 |
.48 |
.30 |
.33 |
.46 |
| KLA/ATP | .71 |
.64 |
.50 |
.41 |
.33 |
.32 |
.42 |
|
Mm.33565 9 | |
160333365 |
Unknown |
KLA | 5.54 |
4.69 |
3.93 |
3.03 |
2.00 |
1.91 |
1.69 |
| ATP | .98 |
.81 |
1.01 |
.78 |
.68 |
1.71 |
1.10 |
| KLA/ATP | 5.05 |
4.44 |
5.07 |
2.38 |
1.34 |
1.88 |
2.00 |
|
Mm.42163
| |
157951683 |
Unknown |
KLA | 1.15 |
1.26 |
1.21 |
1.33 |
1.13 |
1.06 |
.99 |
| ATP | 1.07 |
1.05 |
1.10 |
1.32 |
1.03 |
1.01 |
1.00 |
| KLA/ATP | 1.19 |
1.16 |
1.15 |
1.47 |
1.11 |
1.12 |
.96 |
|
Mm.4387 | |
133892666 |
Unknown |
KLA | .85 |
.87 |
.85 |
.89 |
.77 |
.91 |
1.18 |
| ATP | 1.01 |
1.01 |
.87 |
1.07 |
.75 |
.86 |
.93 |
| KLA/ATP | .88 |
.86 |
.77 |
.81 |
.72 |
.91 |
.84 |
|
Mm.5126 | |
158508678 |
Unknown |
KLA | .70 |
.71 |
.73 |
.79 |
.87 |
1.11 |
1.25 |
| ATP | 1.22 |
1.37 |
1.08 |
1.54 |
1.38 |
1.01 |
1.26 |
| KLA/ATP | .85 |
.83 |
.75 |
.90 |
1.12 |
.96 |
1.17 |
|
Mm.80682
| |
94369627 |
Unknown |
KLA | .96 |
1.00 |
.97 |
.97 |
1.07 |
1.05 |
.99 |
| ATP | .97 |
1.02 |
.98 |
1.01 |
1.01 |
1.06 |
.96 |
| KLA/ATP | 1.00 |
.93 |
1.02 |
1.08 |
.98 |
.95 |
.97 |
|
Myd88 | |
NM_010851 |
myeloid differentiation primary response gene 88 (Myd88), mRNA [NM_010851] |
KLA | 3.35 |
3.51 |
3.91 |
4.13 |
4.13 |
3.62 |
2.53 |
| ATP | .99 |
.96 |
.79 |
.75 |
.93 |
2.15 |
1.60 |
| KLA/ATP | 3.37 |
3.52 |
3.52 |
3.48 |
2.81 |
3.03 |
3.33 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkbia | |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Ngf | |
NM_013609 |
nerve growth factor (Ngf), transcript variant A, mRNA [NM_013609] |
KLA | .99 |
.98 |
.97 |
.99 |
.97 |
1.10 |
1.05 |
| ATP | .94 |
1.03 |
.99 |
1.00 |
.93 |
1.05 |
1.01 |
| KLA/ATP | .94 |
1.01 |
.99 |
.98 |
.98 |
1.11 |
1.02 |
|
Ntrk1 | |
NM_001033124 |
neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] |
KLA | .95 |
.96 |
1.03 |
1.03 |
.95 |
1.01 |
1.02 |
| ATP | 1.04 |
.98 |
.98 |
1.07 |
.99 |
1.01 |
1.02 |
| KLA/ATP | .97 |
1.03 |
1.10 |
1.02 |
1.05 |
1.00 |
.97 |
|
Pik3ca | |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca | |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb | |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd | |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd | |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg | |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 | |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 | |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 | |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 | |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Ppp3ca | |
NM_008913 |
protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] |
KLA | .76 |
.85 |
.81 |
.85 |
.73 |
.70 |
.52 |
| ATP | .96 |
.78 |
.55 |
.46 |
.31 |
.33 |
.48 |
| KLA/ATP | .74 |
.64 |
.52 |
.42 |
.37 |
.36 |
.45 |
|
Ppp3cb | |
AK135203 |
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] |
KLA | 1.74 |
1.57 |
1.91 |
1.59 |
1.47 |
1.26 |
1.40 |
| ATP | 1.17 |
1.03 |
1.30 |
1.00 |
.81 |
.62 |
1.37 |
| KLA/ATP | 1.68 |
1.70 |
1.91 |
1.37 |
1.09 |
.47 |
1.13 |
|
Ppp3cb | |
AK171904 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] |
KLA | 1.29 |
1.29 |
1.21 |
1.15 |
1.22 |
1.13 |
1.28 |
| ATP | .90 |
.86 |
.80 |
.98 |
.94 |
.73 |
.92 |
| KLA/ATP | 1.06 |
1.03 |
.77 |
1.04 |
.92 |
.68 |
.90 |
|
Ppp3cb | |
NM_008914 |
protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] |
KLA | 1.21 |
1.29 |
1.38 |
1.24 |
1.29 |
1.08 |
1.23 |
| ATP | 1.15 |
1.31 |
1.09 |
1.29 |
.86 |
.60 |
.64 |
| KLA/ATP | 1.33 |
1.40 |
1.04 |
1.28 |
.79 |
.58 |
.73 |
|
Ppp3cc | |
AK037563 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] |
KLA | 1.27 |
1.18 |
1.21 |
1.15 |
1.01 |
.92 |
1.36 |
| ATP | .96 |
1.09 |
1.10 |
1.03 |
.85 |
1.06 |
1.47 |
| KLA/ATP | 1.17 |
1.24 |
1.07 |
1.13 |
.91 |
.88 |
1.36 |
|
Ppp3cc | |
NM_008915 |
protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] |
KLA | 1.64 |
1.81 |
1.79 |
1.35 |
.90 |
.70 |
1.31 |
| ATP | .90 |
.90 |
1.13 |
.93 |
.86 |
1.40 |
1.60 |
| KLA/ATP | 1.45 |
1.62 |
1.74 |
1.47 |
1.04 |
1.01 |
1.31 |
|
Ppp3r1 | |
NM_024459 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] |
KLA | 1.02 |
1.17 |
.93 |
1.27 |
1.15 |
1.30 |
1.30 |
| ATP | .97 |
.95 |
.77 |
.91 |
.99 |
1.18 |
1.10 |
| KLA/ATP | 1.12 |
1.04 |
.88 |
1.00 |
1.10 |
1.10 |
1.07 |
|
Ppp3r2 | |
NM_001004025 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] |
KLA | 1.03 |
1.05 |
1.06 |
1.08 |
1.12 |
1.05 |
1.04 |
| ATP | 1.00 |
1.02 |
1.04 |
1.04 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.04 |
1.12 |
1.03 |
1.09 |
1.00 |
.99 |
1.00 |
|
Prkaca | |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
Prkacb | |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
Prkar1a | |
NM_021880 |
protein kinase, cAMP dependent regulatory, type I, alpha (Prkar1a), mRNA [NM_021880] |
KLA | 1.03 |
1.01 |
1.14 |
.97 |
1.05 |
.93 |
.85 |
| ATP | 1.14 |
1.32 |
1.06 |
1.24 |
1.00 |
.62 |
.68 |
| KLA/ATP | 1.16 |
1.24 |
.83 |
1.13 |
.84 |
.79 |
.48 |
|
Prkar1b | |
NM_008923 |
protein kinase, cAMP dependent regulatory, type I beta (Prkar1b), mRNA [NM_008923] |
KLA | 1.02 |
1.05 |
.85 |
.95 |
.90 |
.98 |
1.26 |
| ATP | 1.05 |
1.12 |
.95 |
1.12 |
1.12 |
1.06 |
1.23 |
| KLA/ATP | 1.00 |
.97 |
.81 |
.90 |
.93 |
1.06 |
1.05 |
|
Prkar2a | |
NM_008924 |
protein kinase, cAMP dependent regulatory, type II alpha (Prkar2a), mRNA [NM_008924] |
KLA | .70 |
.65 |
.56 |
.52 |
.41 |
.48 |
.82 |
| ATP | 1.05 |
1.27 |
.85 |
1.05 |
.74 |
.70 |
.84 |
| KLA/ATP | .71 |
.72 |
.45 |
.56 |
.41 |
.51 |
.71 |
|
Prkar2b | |
NM_011158 |
protein kinase, cAMP dependent regulatory, type II beta (Prkar2b), mRNA [NM_011158] |
KLA | .83 |
.76 |
.76 |
.67 |
.34 |
.43 |
.62 |
| ATP | .82 |
.79 |
1.08 |
.71 |
.69 |
2.46 |
.55 |
| KLA/ATP | .65 |
.74 |
.95 |
.63 |
.42 |
.70 |
1.19 |
|
Prkx | |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Ripk1 | |
NM_009068 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (Ripk1), mRNA [NM_009068] |
KLA | 1.32 |
1.33 |
1.50 |
1.09 |
1.00 |
1.11 |
1.13 |
| ATP | .98 |
.94 |
.60 |
.59 |
1.35 |
1.56 |
1.45 |
| KLA/ATP | 1.48 |
1.30 |
1.01 |
1.05 |
1.36 |
1.53 |
1.37 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf10 b | |
NM_020275 |
tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b), mRNA [NM_020275] |
KLA | 1.29 |
1.24 |
1.23 |
1.14 |
.96 |
.88 |
.87 |
| ATP | .99 |
1.04 |
1.06 |
1.14 |
.95 |
1.10 |
1.15 |
| KLA/ATP | 1.26 |
1.26 |
1.21 |
1.23 |
1.03 |
.93 |
.93 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Tnfsf10 | |
NM_009425 |
tumor necrosis factor (ligand) superfamily, member 10 (Tnfsf10), mRNA [NM_009425] |
KLA | 31.48 |
31.73 |
32.62 |
36.94 |
28.34 |
23.40 |
4.96 |
| ATP | 1.06 |
.93 |
1.28 |
1.24 |
1.07 |
2.74 |
3.33 |
| KLA/ATP | 28.07 |
30.23 |
43.53 |
33.98 |
27.97 |
18.71 |
17.43 |
|
Tradd | |
NM_001033161 |
TNFRSF1A-associated via death domain (Tradd), mRNA [NM_001033161] |
KLA | .77 |
.71 |
.82 |
.89 |
.89 |
1.11 |
1.06 |
| ATP | 1.00 |
.90 |
1.01 |
.73 |
.59 |
1.34 |
1.50 |
| KLA/ATP | .79 |
.73 |
.83 |
.63 |
.72 |
1.11 |
1.73 |
|
Traf2 | |
NM_009422 |
Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] |
KLA | 3.38 |
3.62 |
3.49 |
3.36 |
3.49 |
3.39 |
2.68 |
| ATP | .97 |
1.04 |
1.00 |
1.10 |
1.54 |
2.40 |
1.55 |
| KLA/ATP | 3.38 |
3.16 |
2.93 |
2.74 |
2.67 |
3.11 |
4.70 |
|
Trp53 | |
NM_011640 |
transformation related protein 53 (Trp53), mRNA [NM_011640] |
KLA | 1.25 |
1.37 |
1.11 |
.86 |
.72 |
.71 |
.95 |
| ATP | 1.15 |
1.32 |
.90 |
1.85 |
1.26 |
.68 |
.70 |
| KLA/ATP | 1.66 |
1.49 |
.80 |
1.76 |
.81 |
.65 |
.74 |
|
Xiap | |
NM_009688 |
X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] |
KLA | 1.61 |
1.63 |
1.62 |
1.52 |
1.34 |
1.27 |
1.11 |
| ATP | 1.03 |
1.01 |
.99 |
.96 |
.88 |
1.19 |
1.25 |
| KLA/ATP | 1.64 |
1.63 |
1.54 |
1.33 |
1.08 |
1.19 |
1.72 |
|